Novocure Ltd (NVCR)

[herbied47]

Consider please...
-- The LUNAR trial is the first study in more than seven years to show a significant improvement in overall survival in metastatic non-small cell lung cancer post-platinum chemotherapy.
-- How is NSCLC treated in China? In China, platinum-based chemotherapy is standard of care for treating stage IV NSCLC patients, unlike the USA, where checkpoint inhibitors are the dominant choice in first-line.
-- Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China
United States
Lung cancer incidence (overall): 35.1 per 100,000
Lung cancer mortality rate: 27.8 per 100,000
Smoking prevalence (male): 14.4%
Smoking prevalence (female): 11.7%
Outdoor air pollution: 7.4 µg/m3
Indoor air pollution: 0.2% of the population
China
Lung cancer incidence (overall): 35.1 per 100,000
Lung cancer mortality rate: 36.2 per 100,000
Smoking prevalence (male): 44.8%
Smoking prevalence (female): 2%
Outdoor air pollution: 53 µg/m3
Indoor air pollution: 32% of the population
** The stock price reaction to LUNAR is based ENTIRELY on comments made by US physicians and US ICI standard of care.